Haemoglobin (g/dL) · patients with anaemia
1 finding from 1 review
Intervention not reported
Overall quality of life change score ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall social functioning change ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall social functioning change ‐ 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall quality of life change score ‐ 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall anxiety change ‐ Up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall emotional well‐being/mental health change ‐ up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall fatigue change ‐ Up to 12 weeks' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall fatigue change ‐ More than 12 weeks less than 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall pain · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall sexuality change ‐ 6 months' · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Intervention not reported
Overall sleep disturbance · Cancer survivors who have completed active cancer treatment
1 finding from 1 review
Balance ( · patients with neurodegenerative disease
1 finding from 1 review
Gait Timed Up and Go test · patients with neurodegenerative disease
1 finding from 1 review
Balance ( · patients with neurodegenerative disease
1 finding from 1 review
Gait Time Up and Go test and Stand‐walk‐sit test · patients with neurodegenerative disease
1 finding from 1 review
UPDRS III UPDRS scale (motor score). Scale from: 0 to 56. · patients with neurodegenerative disease
1 finding from 1 review
Quality of life · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found